Wool Suh1, Changwon Kee. 1. Department of Ophthalmology, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
Abstract
BACKGROUND: To evaluate the effect of bevacizumab in trabeculectomies with 5-fluorouracil (5-FU). METHODS:Thirty-six patients with uncontrolled glaucoma were included. Twelve patients underwenttrabeculectomies with intracameral and subconjunctival injections of bevacizumab (1.25 mg/0.05 mL) and subconjunctival injections of 5-FU (5.0 mg/0.5 mL). The control group underwent trabeculectomies with subconjunctival injections of only 5-FU (5.0 mg/0.5 mL). The outcome measures, including best-corrected visual acuity, intraocular pressure (IOP), number of IOP-lowering medications, the assessment of bleb, and surgical complications, were evaluated until postoperative 24 months. RESULTS: At each follow-up visit, there were no statistically significant differences between the 2 groups with regard to all outcome measures (P>0.05). The cumulative probabilities of surgical success were 50% and 58.33% in trabeculectomy with bevacizumab and 5-FU and in trabeculectomy with 5-FU, respectively (P=0.68, log-rank test). CONCLUSIONS:Bevacizumab may not exert significant additive effects in trabeculectomy when administered in conjunction with 5-FU.
RCT Entities:
BACKGROUND: To evaluate the effect of bevacizumab in trabeculectomies with 5-fluorouracil (5-FU). METHODS: Thirty-six patients with uncontrolled glaucoma were included. Twelve patients underwent trabeculectomies with intracameral and subconjunctival injections of bevacizumab (1.25 mg/0.05 mL) and subconjunctival injections of 5-FU (5.0 mg/0.5 mL). The control group underwent trabeculectomies with subconjunctival injections of only 5-FU (5.0 mg/0.5 mL). The outcome measures, including best-corrected visual acuity, intraocular pressure (IOP), number of IOP-lowering medications, the assessment of bleb, and surgical complications, were evaluated until postoperative 24 months. RESULTS: At each follow-up visit, there were no statistically significant differences between the 2 groups with regard to all outcome measures (P>0.05). The cumulative probabilities of surgical success were 50% and 58.33% in trabeculectomy with bevacizumab and 5-FU and in trabeculectomy with 5-FU, respectively (P=0.68, log-rank test). CONCLUSIONS:Bevacizumab may not exert significant additive effects in trabeculectomy when administered in conjunction with 5-FU.